Evidence map›Paper›PMID 42653771›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities.

Huayan Li, Xiying He, Ting Cao, Jinfeng Huang, Bojun Chen, Lijing Xu, Yanxiao Yang, Gang Li, Lei Xiong

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huayan LiThe First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.ORCID 0009-0003-3721-7449
Xiying HeThe First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.ORCID 0009-0001-5982-8596
Ting CaoThe First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.
Jinfeng HuangThe First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.
Bojun ChenThe Second Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.
Lijing XuThe First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.
Yanxiao YangThe First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.
Gang LiCollege of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming 650500, China.
Lei XiongThe First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China.

Funding

National Natural Science Foundation of China 82360953National Natural Science Foundation of China 82575146Yunnan Province Science and Technology Department 202301AS070084Yunnan Province Science and Technology Department 202301AT070258
6 · The paper itself

Abstract

Depression is a leading cause of disability worldwide, and currently available antidepressants are limited by delayed therapeutic onset, inadequate efficacy in some patients, and adverse effects. G protein-coupled receptors (GPCRs), the largest family of membrane receptors in the central nervous system, regulate neurotransmission, neuroplasticity, neuroinflammation, stress responses, and reward processing, and are therefore important targets for antidepressant drug development. Natural products are a rich source of structurally diverse bioactive compounds, many of which show antidepressant-like effects through the modulation of GPCR-mediated signaling pathways. In this narrative review, we summarize the roles of major GPCR families implicated in depression and provide an updated overview of natural products that modulate these receptors. We particularly emphasize receptor-specific mechanisms, downstream signaling networks, and the pharmacological actions of representative natural compounds. We also highlight emerging concepts in GPCR biology, including receptor heteromerization, signaling bias, and allosteric modulation, that may create new opportunities for antidepressant discovery. Finally, we discuss current challenges related to target validation, pharmacokinetics, and clinical translation. Collectively, these insights support further investigation of natural product-derived GPCR modulators as potential leads for next-generation antidepressant development.

Indexed as

antidepressant drug discoverycannabinoid receptorsdepressionG protein-coupled receptorsmedicinal chemistrynatural productsneuroinflammationserotonin receptorssignaling pathways

Identifiers

PMID42653771
PMCPMC13516124

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.